ZBP1 Covalent PROTAC-1

ZBP1 Covalent PROTAC-1 (C-PROTAC) forms stable covalent bonds with nucleophilic groups on the wild-type ZBP1 Zα domain, resulting in efficient labeling, which is significantly reduced in mutant ZBP1^G12C Zα domains with altered nucleophilic residues^[1].
ZBP1 Covalent PROTAC-1 (0-400 nM) exhibits good biocompatibility with no cytotoxicity in unspecified cells^[1].
ZBP1 Covalent PROTAC-1 (12.5-200 nM; 0-48 h) potently degrades CBL0137-induced ZBP1 in unspecified cells with a DC₅₀ of 25.69 nM and a degradation half-life of 17.03 h, exhibiting at least 3-fold greater efficacy than traditional PROTAC^[1].
ZBP1 Covalent PROTAC-1 (C-PROTAC) (100 nM) mediates ZBP1 degradation in unspecified cells via a proteasome-dependent pathway, as degradation is blocked by the proteasome inhibitor MG132^[1].
ZBP1 Covalent PROTAC-1 (C-PROTAC) (12.5-200 nM) inhibits the ZBP1-dependent necroptotic pathway in unspecified cells by reducing phosphorylation of RIPK3 and MLKL, without affecting Caspase-8 expression related to apoptosis^[1].
ZBP1 Covalent PROTAC-1 (C-PROTAC) (100 nM) degrades virus-induced ZBP1, restores cell viability to 95.8%, and significantly reduces proinflammatory cytokine expression in H1N1 influenza virus-infected cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.